Abstract: The present invention relates to the treatment of cancer in a subject, wherein cancer cells of said subject overproduce H2O2 and have a level of GSH below 0.5 nmol for 25 000 cells, with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate. It also relates to a method for selecting a subject suffering from a cancer and who will most likely benefit from a treatment with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate.

Abstract: The invention relates to a specific substrate on an ALDH isoenzyme, to a composition comprising at least one such substrate, to a diagnostic marker comprising such a substrate, and to the uses thereof and associated methods.

Abstract: The present invention relates to novel aminoesters compounds or its pharmaceutically acceptable salts or optical isomers, racemates, diastereoisomers, enantiomers or tautomers. The present invention also relates to their process of preparation and to these compounds for use as a medicament, in particular for the treatment or the prevention of cancer. The present invention further relates to an antibody drug conjugate comprising such compounds.

Abstract: The present invention concerns an ex vivo method for the monitoring of apoptosis which is based on the detection of free gamma-glutamyl-L-epsilon-Lysine (GGEL) in a biological sample of a subject with a monoclonal antibody specific to GGEL. The invention also relates to the monoclonal antibody specific to GGEL, as well as to diagnostic kits containing such a ligand.

Abstract: The present invention relates to a combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof, in particular the S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, and more particularly the 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate, and a compound able to increase H2O2 level in cancer cells of a subject, in particular for use for the treatment of cancer in a subject, wherein cancer cells of said subject do not overproduce H2O2 in comparison to a control value and have a level of GSH below 5 nmol for 25000 cells.

Abstract: The invention relates to a specific substrate on an ALDH isoenzyme, to a composition comprising at least one such substrate, to a diagnostic marker comprising such a substrate, and to the uses thereof and associated methods.

Abstract: The present invention concerns an ex vivo method for the monitoring of apoptosis which is based on the detection of free gamma-glutamyl-L-epsilon-Lysine (GGEL) in a biological sample of a subject with a monoclonal antibody specific to GGEL. The invention also relates to the monoclonal antibody specific to GGEL, as well as to diagnostic kits containing such a ligand.

Abstract: The present invention relates to a combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof, in particular the S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, and more particularly the 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate, and a compound able to increase H2O2 level in cancer cells of a subject, in particular for use for the treatment of cancer in a subject, wherein cancer cells of said subject do not overproduce H2O2 in comparison to a control value and have a level of GSH below 5 nmol for 25000 cells.

Abstract: The present invention relates to the treatment of cancer in a subject, wherein cancer cells of said subject overproduce H2O2 and have a level of GSH below 0.5 nmol for 25 000 cells, with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate. It also relates to a method for selecting a subject suffering from a cancer and who will most likely benefit from a treatment with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate.

Abstract: A process related to sodium chemicals production, including the processing of bicarbonate containing solutions obtained by solution mining of trona, nahcolite or wegscheiderite reserves and the lake waters containing bicarbonates, includes the steps of purification, evaporation-decarbonation, crystallization, centrifuging, and drying.

Abstract: A process related to sodium chemicals production, including the processing of bicarbonate containing solutions obtained by solution mining of trona, nahcolite or wegscheiderite reserves and the lake waters containing bicarbonates, includes the steps of purification, evaporation-decarbonation, crystallization, centrifuging, and drying.